NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Sapreme Technologies BV

Sapreme Technologies BV

Private
NetherlandsHealthcare & Life Scienceshttps://sapreme.com/

Last Round

Series A

Oct 7, 2021

Total Funding Raised

$25.01M

Company Overview

Sapreme Technologies BV is a biotechnology company that develops a proprietary endosomal escape platform to enable the cytosolic delivery of macromolecule therapeutics for genetically driven diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

RNA therapeuticsendosomal escapeintracellular deliveryantisense oligonucleotidesASOssiRNAdrug delivery platformdrug delivery techbiotechnologybiotechdrug discoverylarge-molecule therapeuticsneuromuscular diseasescardiometabolic diseasesglycosylated triterpenoids

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Sapreme Technologies BV Comparables

Compare Sapreme Technologies BV with similar companies based on industry and business-model similarity.

Sapreme Technologies BV comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
CyGenica
86%
Libera Bio
81%
NanoSyrinx
80%

Sapreme Technologies BV Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AOct 7, 2021
GrantFeb 20, 2019
SeedJan 1, 2016

Key People

Founding team and executive leadership

Marco Timmers

Chief Executive Officer

Executive Team

Chris Huiskamp

Chief Financial Officer

Executive Team

Sapreme Technologies BV Investors

Notable investors and investment history

Sapreme Technologies BV investors
InvestorRounds
European UnionGrant
East Netherlands Development Agency (Oost NL)Series A
Aglaia Oncology FundsSeries A, Seed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Oct 7, 2021

    $17.3M round led by Aglaia Oncology Funds

  • Feb 20, 2019

    Received $8M from the European Union.

Sapreme Technologies BV Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Sapreme Technologies BV Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Sapreme Technologies BV's valuation, stock price, and market status.

Firmographic Details

HeadquartersNetherlands
Employee Range15
Year Founded2016
Last FundingOct 7, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.